MGD
Showing 1 - 25 of 169
Meibomian Gland Dysfunction, Dry Eye Disease Trial in Miami, Marlborough, Buenos Aires (Nordlys SWT IPL, Meibomian Gland
Recruiting
- Meibomian Gland Dysfunction
- Dry Eye Disease
- Nordlys SWT IPL
- Meibomian Gland Expression (MGX)
-
Miami, Florida
- +2 more
Sep 26, 2023
Meibomian Gland Dysfunction Trial in Sydney (AZR-MD-001 ointment/semi-solid drug)
Completed
- Meibomian Gland Dysfunction
- AZR-MD-001 ointment/semi-solid drug
-
Sydney, New South Wales, AustraliaFiona Stapleton
Apr 25, 2022
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1 Trial in New
Not yet recruiting
- Human Immunodeficiency Virus I Infection
- +2 more
- MGD020
- MGD014
- (no location specified)
Jun 27, 2022
Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid Trial in Tianjin (Routine preoperative and postoperative
Completed
- Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid
- Routine preoperative and postoperative anti-infection therapy
- +2 more
-
Tianjin, Tianjin, ChinaTianjin medical university eye hosipital
Mar 4, 2023
Dry Eye, Meibomian Gland Dysfunction Trial in Guangzhou (Warm compresses, 3% Diquafosol Sodium Eye Drops)
Not yet recruiting
- Dry Eye
- Meibomian Gland Dysfunction
- Warm compresses
- 3% Diquafosol Sodium Eye Drops
-
Guangzhou, Guangdong, ChinaZhongshan Ophthalmic Center, Sun Yat-Sen University
Aug 5, 2022
HIV-1-infection Trial in Chapel Hill (MGD014)
Completed
- HIV-1-infection
- MGD014
-
Chapel Hill, North CarolinaUniversity of North Carolina Chapel Hill
Aug 31, 2022
Dry Eye Trial in Toronto, Waterloo (I-DROP MGD, Thealoz Duo)
Completed
- Dry Eye
- I-DROP MGD
- Thealoz Duo
-
Toronto, Ontario, Canada
- +1 more
Mar 28, 2022
Advanced Hepatocellular Carcinoma (HCC) Trial in Hong Kong (MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate)
Terminated
- Advanced Hepatocellular Carcinoma (HCC)
- MGD013 monotherapy
- MGD013 in combination with Brivanib Alaninate
-
Hong Kong, Hong Kong, ChinaPrince of Wales Hospital
Jun 8, 2022
Dry Eye Disease, Meibomian Gland Dysfunction Trial in New York, Harrisburg (IPL_RF_MGX)
Recruiting
- Dry Eye Disease
- Meibomian Gland Dysfunction
- IPL_RF_MGX
-
New York, New York
- +1 more
Aug 1, 2022
Quantitative Assessment of Lid Margin Vascularity Using SS-OCTA
Not yet recruiting
- Ss-octa
- +2 more
- (no location specified)
Oct 15, 2023
Relapsed Acute Myeloid Leukemia Trial in Saint Louis (Flotetuzumab, Donor lymphocyte infusion)
Recruiting
- Relapsed Acute Myeloid Leukemia
- Flotetuzumab
- Donor lymphocyte infusion
-
Saint Louis, MissouriWashington University School of Medicine
Sep 7, 2022
MGD-Meibomian Gland Dysfunction Trial in Wuhan, Hangzhou (Intense pulsed light, 0.3% hyaluronic acid eye drops)
Completed
- MGD-Meibomian Gland Dysfunction
- Intense pulsed light
- 0.3% hyaluronic acid eye drops
-
Wuhan, Hubei, China
- +2 more
Sep 11, 2023
Healthy Subjects Trial in Baltimore (MGD010, Placebo, Hepatitis A vaccine)
Completed
- Healthy Subjects
- MGD010
- +2 more
-
Baltimore, MarylandPAREXEL Baltimore Early Phase Clinical Unit
Feb 4, 2022
Head Neck Cancer, Squamous Cell Carcinoma of Head and Neck Trial (enoblituzumab, MGA012, MGD013)
Withdrawn
- Head and Neck Cancer
- Squamous Cell Carcinoma of Head and Neck
- enoblituzumab
- +2 more
- (no location specified)
Feb 4, 2022
Colorectal Cancer Metastatic Trial in United States (MGD007 + MGA012)
Completed
- Colorectal Cancer Metastatic
- MGD007 + MGA012
-
New Haven, Connecticut
- +5 more
Feb 4, 2022
Metastatic Cancer, Cervical Cancer Trial in Houston (MGD019)
Not yet recruiting
- Metastatic Cancer
- Cervical Cancer
-
Houston, TexasM D Anderson Cancer Center
Jul 22, 2022
Unresectable, Recurrent or Metastatic Melanoma, Untreated Mucosal or Acral Lentiginous Melanoma Trial in China (MGD013)
Terminated
- Unresectable, Recurrent or Metastatic Melanoma
- Untreated Mucosal or Acral Lentiginous Melanoma
-
Beijing, Beijing, China
- +12 more
Apr 12, 2022
Acute Myeloid Leukemia, AML, AML, Adult Recurrent Trial (flotetuzumab)
No longer available
- Acute Myeloid Leukemia
- +2 more
- flotetuzumab
- (no location specified)
May 24, 2022
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma Trial in United States (MGC018, lorigerlimab)
Recruiting
- Advanced Solid Tumor
- +6 more
- vobramitamab duocarmazine
- lorigerlimab
-
Los Angeles, California
- +7 more
Jan 10, 2023
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation Trial (TP-03, TP-03 Vehicle)
Not yet recruiting
- Meibomian Gland Dysfunction
- +2 more
- TP-03
- TP-03 Vehicle
- (no location specified)
Jul 13, 2022
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,
Not yet recruiting
- Androgen-Independent Prostatic Cancer
- +8 more
- lorigerlimab
- +2 more
- (no location specified)
May 4, 2023
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in
Recruiting
- Recurrent Acute Leukemia
- +16 more
- Acetaminophen
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 22, 2022
Meibomian Gland Dysfunction Trial in Kowloon, Shatin (device, behavioral, drug)
Recruiting
- Meibomian Gland Dysfunction
- Vectored thermal pulsation (VTP) therapy
- +3 more
-
Kowloon, Hong Kong
- +3 more
Nov 26, 2022